Nipro Corp (NPRRF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Nipro Corp $10.96, price $9.40, upside +16.6%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Nipro Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $7.40 – $9.96 · the $9.40 price screens below the $10.96 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Nipro in your weekly email
Every Wednesday you see whether Nipro is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses.
Show more
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical Device business develops, manufactures, and sells medical equipment for injection-infusion and dialysis treatment, and products related to diabetes and cell cultures, as well as the sale of artificial organ-related products. The company's Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations, as well as logistic and distribution services. Its Pharma Packaging business offers glass products and other comprehensive pharmaceutical packaging, such as glass vials, ampoules, and syringes; tube glass; and other parts of pharmaceutical packaging, such as rubber plugs, as well as provides glass for thermos bottles, and lighting and containers. The company also offers business management services. It serves customers in Japan, the Americas, Europe, and rest of Asia. The company was founded in 1947 and is headquartered in Osaka, Japan.
Stock analysis
Nipro Corp (NPRRF) currently trades at $9.40, while our model-based Fair Value estimate is $10.96, implying the stock looks roughly 14.2% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $23.25 per share, and 11 of the 21 models we run sit above the $9.40 price.
Bear case: the Earnings-Based group reads lowest at $2.81, and 10 of the 21 models stay below the price. Evidence for this calculation is high.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Health Care sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Nipro Corp reported revenue of ¥645B in FY2025 versus ¥456B in FY2021, a compound +9.1%/yr. Reported net income was ¥5.1B in FY2025, compounding −22.5%/yr from FY2021.
Key figures
Market cap $1.5B · P/E ratio 21.7 · P/S ratio 0.17 · EPS (TTM) $0.7100 · Net margin 0.8% · Return on equity 9.1% · Return on assets (EBIT) 2.4% · Operating margin 5.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 6% below its 52-week high and 17% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Health Care peers we cover trades at 6% fair-value upside, at 17%, NPRRF screens cheaper than that median.
Fair Value models
Bear $10.96Fair Value $10.96Bull $10.96
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.79/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+9.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−0.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.8%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 4%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about −3.4% a year for the price and +1.9% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 360 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score50 · Above median
Fair Value upside+16.6% · Top 25%
Profitability
Return on equity (TTM)9.1% · Above median
Return on assets1.7% · Above median
Net margin (TTM)3.1% · Below median
Operating margin (TTM)5.0% · Below median
Growth and dividend
Revenue growth7.1% · Above median
Balance sheet
Debt / equity1.42× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Nipro Corp Fair Value". https://www.fairvalue-calculator.com/stock/NPRRF
Frequently asked questions
Is Nipro Corp (NPRRF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $10.96 versus a price of $9.40, about +17% upside (undervalued).
What is the fair value of NPRRF?
Our model-based fair value for Nipro Corp is $10.96 (as of Sep 24, 2026), built from audited fundamentals. The current price: $9.40.
What is the quality score of NPRRF?
Nipro Corp has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nipro Corp (NPRRF)?
Our model-based price target is the fair value of $10.96 (as of Sep 24, 2026) from 21 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Nipro Corp stock forecast for 2026?
Our models put fair value at $10.96, about +17% upside versus a price of $9.40 (undervalued). The calculation is refreshed regularly with new filings.
What is the revenue of Nipro Corp (NPRRF)?
Nipro Corp reported trailing-twelve-month revenue of about ¥484B (latest available figure, as of Sep 24, 2026).
What growth is priced into Nipro Corp (NPRRF)?
For today's price to be fair in a discounted-cash-flow model, Nipro Corp would have to grow free cash flow by -1.4 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +9.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of NPRRF use?
Our models discount Nipro Corp at 9.8 %: a base by market capitalisation (small), damped by beta 0.49, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Nipro Corp that is -1.4 % per year a year over ten years, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has Nipro Corp (NPRRF) delivered so far?
Over the past 4 years revenue at Nipro Corp grew +9.1 % a year. The price currently implies -1.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
What is the free cash flow yield of Nipro Corp (NPRRF)?
The free-cash-flow yield on the price is 28.41 %: that much free cash flow Nipro Corp produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Nipro Corp (NPRRF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nipro Corp it is $10.96 per share (as of Sep 24, 2026), against a price of $9.40. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is Nipro Corp stock overvalued or undervalued in 2026?
As of Sep 24, 2026, NPRRF trades below its calculated fair value: price $9.40, fair value $10.96, a gap of about +17% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NPRRF?
No. The price is what the market pays today ($9.40); the fair value is what the company's own numbers justify ($10.96). For Nipro Corp the two are $1.56 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nipro Corp worth?
The market values Nipro Corp at about $1.5B (market capitalisation, as of Sep 24, 2026). Per share that is $9.40; our models calculate a fair value of $10.96 per share.
What is the P/E ratio of NPRRF?
Nipro Corp trades at a price-to-earnings ratio of 21.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $10.96 is built from several models across several years. Other multiples: P/B 0.8, P/S 0.5, EV/EBITDA 8.6.
How solid is the balance sheet of Nipro Corp (NPRRF)?
Balance-sheet figures for Nipro Corp (as of Sep 24, 2026): return on equity 9.1%, debt of 1.42 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is NPRRF from its 52-week high?
Nipro Corp trades at $9.40, about 6% below its 52-week high of $9.96 and 17% above the low of $8.00 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $10.96 is for.
Which stocks are comparable to Nipro Corp?
From the same area (Health Care) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nipro Corp stock attractive at the current price?
The data as of Sep 24, 2026: price $9.40, calculated fair value $10.96 (+17%), Quality Score 50/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NPRRF calculated?
We run Nipro Corp through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $10.96, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Nipro Corp currently trades 17 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nipro Corp (NPRRF)?
The closing price on Sep 25, 2026 was $9.40. Our model-based fair value is $10.96, about +17% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nipro Corp right now?
The price is below even our cautious bear case ($10.96). The market is more pessimistic than our downside scenario. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Nipro Corp
How large is the market capitalisation of Nipro Corp (NPRRF)?
The market capitalisation of Nipro Corp is $1.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nipro Corp (NPRRF)?
The price-to-sales ratio of Nipro Corp is 0.17 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nipro Corp (NPRRF)?
Earnings per share at Nipro Corp are $0.7100 (price ÷ EPS = P/E 21.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Nipro Corp (NPRRF)?
The net margin of Nipro Corp is 0.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nipro Corp (NPRRF)?
The return on equity (ROE) of Nipro Corp is 9.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nipro Corp (NPRRF)?
On an EBIT basis the return on assets of Nipro Corp is 2.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nipro Corp (NPRRF)?
The operating margin of Nipro Corp is 5.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nipro Corp (NPRRF)?
Revenue at Nipro Corp is growing +7.1% versus a year earlier (3y avg +9.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nipro Corp (NPRRF)?
Earnings per share at Nipro Corp are growing −25.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Nipro Corp (NPRRF) carry?
The net debt of Nipro Corp is ¥498B (fiscal year 2025, ≈ 7.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Nipro Corp in the live analysis
One click puts Nipro Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Sep 24, 2026